Pharmacogenomic applications in clinical drug development

被引：4

作者：

Dracopoli, NC ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Princeton, NJ 08540 USA

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2003年 / 52卷 / Suppl 1期

关键词：

pharmacogenomics; pharmacogenetics; drug discovery; transcription profiling;

D O I：

10.1007/s00280-003-0594-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pharmacogenomics is being increasingly applied to the development of novel oncology drugs. Single nucleotide polymorphism genotyping of known drug-metabolizing and transport genes is used to screen for pharmacokinetic differences in drug exposure, and genome-wide transcription profiling is being widely used to identify expression profiles that can be correlated to pharmacodynamic variables resulting from molecular changes within tumors. Given the relatively low efficacy of most cancer therapies, and the molecular heterogeneity within tumors, pharmacogenomics provides one of the best opportunities for improvements in drug efficacy through effective stratification of patients, and early identification of those individuals most likely to respond effectively to a specific therapeutic approach.

引用

页码：S57 / S60

页数：4

共 10 条

[1]

DeRisi J, 1996, NAT GENET, V14, P457

[2] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].

Golub, TR ;

Slonim, DK ;

Tamayo, P ;

Huard, C ;

Gaasenbeek, M ;

Mesirov, JP ;

Coller, H ;

Loh, ML ;

Downing, JR ;

Caligiuri, MA ;

Bloomfield, CD ;

Lander, ES .

SCIENCE, 1999, 286 (5439) :531-537

[3] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[4] Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm [J].

Krynetski, EY ;

Evans, WE .

PHARMACEUTICAL RESEARCH, 1999, 16 (03) :342-349

[5] Pharmacogenetics and the practice of medicine [J].

Roses, AD .

NATURE, 2000, 405 (6788) :857-865

[6] Genome-based pharmacogenetics and the pharmaceutical industry [J].

Roses, AD .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :541-549

[7] A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms [J].

Sachidanandam, R ;

Weissman, D ;

Schmidt, SC ;

Kakol, JM ;

Stein, LD ;

Marth, G ;

Sherry, S ;

Mullikin, JC ;

Mortimore, BJ ;

Willey, DL ;

Hunt, SE ;

Cole, CG ;

Coggill, PC ;

Rice, CM ;

Ning, ZM ;

Rogers, J ;

Bentley, DR ;

Kwok, PY ;

Mardis, ER ;

Yeh, RT ;

Schultz, B ;

Cook, L ;

Davenport, R ;

Dante, M ;

Fulton, L ;

Hillier, L ;

Waterston, RH ;

McPherson, JD ;

Gilman, B ;

Schaffner, S ;

Van Etten, WJ ;

Reich, D ;

Higgins, J ;

Daly, MJ ;

Blumenstiel, B ;

Baldwin, J ;

Stange-Thomann, NS ;

Zody, MC ;

Linton, L ;

Lander, ES ;

Altshuler, D .

NATURE, 2001, 409 (6822) :928-933

[8] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[9] Gene expression profiling predicts clinical outcome of breast cancer [J].

van't Veer, LJ ;

Dai, HY ;

van de Vijver, MJ ;

He, YDD ;

Hart, AAM ;

Mao, M ;

Peterse, HL ;

van der Kooy, K ;

Marton, MJ ;

Witteveen, AT ;

Schreiber, GJ ;

Kerkhoven, RM ;

Roberts, C ;

Linsley, PS ;

Bernards, R ;

Friend, SH .

NATURE, 2002, 415 (6871) :530-536

[10] An information-intensive approach to the molecular pharmacology of cancer [J].

Weinstein, JN ;

Myers, TG ;

OConnor, PM ;

Friend, SH ;

Fornace, AJ ;

Kohn, KW ;

Fojo, T ;

Bates, SE ;

Rubinstein, LV ;

Anderson, NL ;

Buolamwini, JK ;

vanOsdol, WW ;

Monks, AP ;

Scudiero, DA ;

Sausville, EA ;

Zaharevitz, DW ;

Bunow, B ;

Viswanadhan, VN ;

Johnson, GS ;

Wittes, RE ;

Paull, KD .

SCIENCE, 1997, 275 (5298) :343-349

← 1 →